Skip to main content

Advertisement

Table 1 Clinical characteristics and visual outcomes in patients with herpetic retinal necrosis associated with natalizumab

From: Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab

Publication Age (years) Sex Laterality  
 Kobeleva et al. 49 M Bilateral  
 Saraiva 51 M Unilateral (right eye)  
 Van Tassel et al. 54 F Unilateral (left eye)  
 Current study 34 F Bilateral  
Publication Initial VA Treatment/clinical course Length of follow-up VA at the last follow-up
 Kobeleva et al. Not reported CNS vasculitis and necrotizing retinitis treated with combination of IV acyclovir, high-dose IV methylprednisone and 5 cycles of plasma exchange therapy to accelerate natalizumab clearance. 4 months “Almost completely blind.”
Cyclophosphamide was given after steroids and plasma exchange.
 Saraiva 20/30 OD Natalizumab was discontinued. Oral valacyclovir 1 g TID for 3 months. Oral prednisone initiated 4 days after starting valacyclovir. Propophylatic laser retinal photocoagulation performed 14 days after initiation of antiviral therapy. One month after discontinuing antiviral therapy, the patient developed immune reconstitution inflammatory syndrome. Systemic steroids resolved inflammation. 5 months 20/30 OD
 Van Tassel et al. 20/125 OS Natalizumab was discontinued. IV and intravitreal antivirals were administered. Complicated by late retinal detachment. 2 months 20/125 OS
 Current study 20/25 OD, 20/50 OS Natalizumab was discontinued. IV and intravitreal antivirals were administered. Complicated by late retinal detachment and optic atrophy. 11 months 20/30 OD, HM OS